Compliance and Tolerance to Oral AntiBiotherapy in Osteoarticular Infections (OTABIO)

Study acronym: OTABIO
StatusRecruiting
PhaseNot specified
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 1 year 11 months later Sep 2026 → Sep 13, 2028
See other at-risk trials from Hospices Civils de Lyon

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary and study completion pushed from Sep 2026 to Sep 13, 2028
    • Eligibility criteria expanded, about 9 words
  2. Re-verified, no change to tracked fieldsv5
  3. Primary and study completion dates: Dec 2024 to Sep 2026
    • Start date changed from estimate of Sep 2022 to Jun 13, 2024
    v4
  4. Primary and study completion dates: May 2024 to Dec 2024
    • Start date: Feb 2022 to Sep 2022
    v3
  5. Trial status: Not Yet Recruiting to Recruiting
    • Site details revised
    v2
  6. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
Bone and joint infections (BJI) are most often bacterial infections that can occur after surgery or de novo. They are rarely fatal in the short term, but are associated with significant morbidity, impaired quality of life and significant costs. Treatment of BJI is based on antibiotic therapy, often combined with surgery. Antibiotic therapy, at high doses, lasts a minimum of 6 weeks. It can be responsible for severe adverse effects. These characteristics (prolonged duration, multiple daily doses, and adverse effects) are known to negatively affect treatment adherence in general.
Trial Details
NCT Number NCT05202964
Lead Sponsor Hospices Civils de Lyon
Conditions
(from sponsor)		 Drug-Related Side Effects and Adverse Reactions, Treatment Adherence and Compliance
Related terms Drug-Related Side Effects and Adverse Reactions, Treatment Adherence and Compliance
Enrollment 60 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov